Keros Therapeutics Files Prospectus For Offering $350M Mixed Shelf; May Offer $100M Common Shares Under Sales Agreement With Leering Partners

Benzinga Newsdesk www.benzinga.com Neutral 92.3%

Neg 0% Neu 92.3% Pos 0%

SEC.

Comments

No comments yet. Be the first!